The FDA has let down renal cancer patients with its Tivozanib decision. Strategies FDA’s flawed call on Aveo’s Tivozanib
We did some housecleaning in the Health Care portfolio. Strategies Reshuffling the lineup for my Healthcare portfolio
Across the board the relative safety profile of Tivo stands out. Strategies How Aveo’s Tivo cancer drug stacks up against rivals
